Clinical Trials Directory

Trials / Completed

CompletedNCT00346034

This Study is An Open-Label Trial Of Pregabalin In Patients With Fibromyalgia

A 12 Week, Open-Label, Safety Trial Of Pregabalin In Patients With Fibromyalgia

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
357 (actual)
Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The main purpose of this protocol is to evaluate the long-term safety of pregabalin in patients who participated in the previous fibromyalgia Study A0081100 and who wish to receive open-label pregabalin therapy.

Conditions

Interventions

TypeNameDescription
DRUGPregabalin150 to 600mg/day

Timeline

Start date
2006-12-01
Primary completion
2008-02-01
Completion
2008-02-01
First posted
2006-06-29
Last updated
2021-01-22
Results posted
2009-03-13

Locations

51 sites across 12 countries: Canada, Denmark, France, Germany, India, Italy, Netherlands, Portugal, South Korea, Sweden, Switzerland, United Kingdom

Source: ClinicalTrials.gov record NCT00346034. Inclusion in this directory is not an endorsement.

This Study is An Open-Label Trial Of Pregabalin In Patients With Fibromyalgia (NCT00346034) · Clinical Trials Directory